DTIL

PRECISION BIOSCIENCES INC

Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE · CIK 0001357874
$6.10 -1.13% $157.4M
High Impact Filing (7/10)3 New Institutional Positions3 Institutional Exits
Vol
Market Cap$157.4M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders32 funds
Inst. Value$22.6M
Inst. Activity3 buys / 3 sells
SEC Reports5
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001357874·Prev Close $6.17

Recent Activity

Jun 3, 2026 Insider
Germano Geno J was granted 20,979 shares
Director
Jun 3, 2026 Insider
Frankel Stanley was granted 20,979 shares
Director
Jun 3, 2026 Insider
Pire Shari Lisa was granted 20,979 shares
Director
May 27, 2026 SEC
Precision BioSciences announced new and late-breaking clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in
8-K — Impact 7/10
May 26, 2026 SEC
Precision BioSciences held its 2026 annual meeting on May 21, 2026, with roughly 86% of shares represented. Shareholders
8-K — Impact 4/10
May 5, 2026 SEC
Precision BioSciences reported Q1 2026 revenue of $10.8M (up from ~$0.1M YoY) and a net loss of $(0.75)/share, narrowing
8-K — Impact 4/10
Inst.
DRIEHAUS CAPITAL MANAGEMENT LLC — ADD
995,371 shares ($5.5M)
Inst.
MARSHALL WACE, LLP — DOUBLED
415,671 shares ($2.3M)

Price Targets

$29.60 +385.2% upside Strong Buy
Current $6.10 Low $19.00 Median $20.00 High $60.00 5 analysts
$19.00 $60.00

Analyst Ratings

Strong Buy90% buy · 10 analysts
4Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 9, 2026 Oppenheimer INITIATE Outperform
May 27, 2026 HC Wainwright & Co. REITERATE Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.67 ▼ -11.7% $-0.81 — $-0.50 69% YoY 3
Next Q $-0.65 ▼ -6.0% $-0.72 — $-0.51 65% YoY 3
Current FY $-2.49 ▼ -14.6% $-3.12 — $-1.70 32% YoY 3
Next FY $-1.89 ▲ +1.1% $-2.38 — $-1.45 24% YoY 3

Latest Reports

BULLISH 8-K 7/10
Precision BioSciences announced new and late-breaking clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in
May 27, 2026
NEUTRAL 8-K 4/10
Precision BioSciences held its 2026 annual meeting on May 21, 2026, with roughly 86% of shares represented. Shareholders
May 26, 2026

Top Institutional Holders

FundValueMove
DRIEHAUS CAPITAL MANAGEMENT LLC$5.5MADD
VANGUARD CAPITAL MANAGEMENT LLC$5.0M—
MARSHALL WACE, LLP$2.3MDOUBLED
TWO SIGMA INVESTMENTS, LP$1.7MADD
RENAISSANCE TECHNOLOGIES LLC$1.2MTRIM

Recent Insider Trades

DateInsiderTypeValue
Jun 3, 2026Germano GenoA$0.00
Jun 3, 2026Frankel StanleyA$0.00
Jun 3, 2026Pire ShariA$0.00
Jun 3, 2026Buehler KevinA$0.00
Jun 3, 2026Brown MelindaA$0.00
32 institutional holders with $22.6M total value (4,112,834 shares) as of 2026-Q1. Top holders: DRIEHAUS, VANGUARD, MARSHALL.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1DRIEHAUS CAPITAL MANAGEMENT LLC995,371$5.5M24.2%ADD +26.4%
2VANGUARD CAPITAL MANAGEMENT LLC910,740$5.0M22.1%—
3MARSHALL WACE, LLP415,671$2.3M10.1%DOUBLED +486.2%
4TWO SIGMA INVESTMENTS, LP307,790$1.7M7.5%ADD +67.9%
5RENAISSANCE TECHNOLOGIES LLC223,177$1.2M5.4%TRIM -31.6%
6BlackRock, Inc.199,761$1.1M4.9%ADD +70.5%
7VANGUARD FIDUCIARY TRUST CO155,626$855.9K3.8%—
8Alyeska Investment Group, L.P.138,825$763.5K3.4%NEAR_EXIT -82.6%
9MORGAN STANLEY122,277$672.5K3.0%DOUBLED +852.9%
10CITADEL ADVISORS LLC115,952$637.7K2.8%—
11COMMONWEALTH EQUITY SERVICES, LLC112,671$619.7K2.7%ADD +67.1%
12STATE STREET CORP72,942$401.2K1.8%ADD +54.8%
13SUSQUEHANNA INTERNATIONAL GROUP, LLP64,462$354.5K1.6%—
14GOLDMAN SACHS GROUP INC39,752$218.6K1.0%—
15Hudson Bay Capital Management LP37,141$204.3K0.9%—
16Point72 Asset Management, L.P.35,593$195.8K0.9%—
17Brevan Howard Capital Management LP34,442$189.4K0.8%—
18BANK OF AMERICA CORP /DE/27,416$150.8K0.7%DOUBLED +167.6%
19Trexquant Investment LP26,066$143.4K0.6%TRIM -35.2%
20SUSQUEHANNA INTERNATIONAL GROUP, LLP20,400$112.2K0.5%—

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
DRIEHAUS CAPITAL MANAGEMENT LLCADD787,700995,371+26.4%$5.5M2026-Q1
MARSHALL WACE, LLPDOUBLED70,915415,671+486.2%$2.3M2026-Q1
RENAISSANCE TECHNOLOGIES LLCTRIM326,477223,177-31.6%$1.2M2026-Q1
Alyeska Investment Group, L.P.NEAR_EXIT798,000138,825-82.6%$763.5K2026-Q1
BANK OF AMERICA CORP /DE/DOUBLED10,24427,416+167.6%$150.8K2026-Q1
Trexquant Investment LPTRIM40,25626,066-35.2%$143.4K2026-Q1
VANGUARD GROUP INCADD492,596906,782+84.1%$3.8M2025-Q4
RENAISSANCE TECHNOLOGIES LLCADD196,177326,477+66.4%$1.4M2025-Q4
BlackRock, Inc.ADD98,699168,331+70.5%$700.3K2025-Q4
TWO SIGMA INVESTMENTS, LPADD83,092139,531+67.9%$580.4K2025-Q4
MORGAN STANLEYDOUBLED10,47499,805+852.9%$415.2K2025-Q4
COMMONWEALTH EQUITY SERVICES, LLCADD55,84593,306+67.1%$388.1K2025-Q4
STATE STREET CORPADD38,14259,042+54.8%$245.6K2025-Q4
DIMENSIONAL FUND ADVISORS LPTRIM43,64123,757-45.6%$98.8K2025-Q4
BANK OF AMERICA CORP /DE/DOUBLED20610,244+4872.8%$42.6K2025-Q4
RENAISSANCE TECHNOLOGIES LLCDOUBLED80,277196,177+144.4%$1.1M2025-Q3
BlackRock, Inc.ADD57,49098,699+71.7%$544.8K2025-Q3
TWO SIGMA INVESTMENTS, LPDOUBLED16,36383,092+407.8%$458.7K2025-Q3
STATE STREET CORPADD26,24238,142+45.3%$210.5K2025-Q3
UBS Group AGTRIM51,60624,476-52.6%$135.1K2025-Q3
Corient Private Wealth LLCNEAR_EXIT101,20610,000-90.1%$55.2K2025-Q3
BANK OF AMERICA CORP /DE/ADD164206+25.6%$1.1K2025-Q3
WELLS FARGO & COMPANY/MNTRIM6835-48.5%$193.002025-Q3
VANGUARD GROUP INCADD281,083405,354+44.2%$1.7M2025-Q2
NATIONAL BANK OF CANADA /FI/ADD5,0007,000+40.0%$29.4K2025-Q2
9 unique insiders with 14 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 3, 2026Germano Geno JDirectorAWARD20,979——
Jun 3, 2026Frankel StanleyDirectorAWARD20,979——
Jun 3, 2026Pire Shari LisaDirectorAWARD20,979——
Jun 3, 2026Buehler KevinDirectorAWARD20,979——
Jun 3, 2026Brown MelindaDirectorAWARD20,979——
Jun 1, 2026Scimeca DarioGeneral Counsel and SecretaryAWARD107,604——
Jun 1, 2026SMITH J. JEFFERSONChief Research OfficerAWARD57,389——
Jun 1, 2026Kelly John AlexanderChief Financial OfficerAWARD193,688——
Jun 1, 2026Amoroso MichaelPresident and CEOAWARD573,888——
May 20, 2026Germano Geno JDirectorEXERCISE21,000——
May 20, 2026Pire Shari LisaDirectorEXERCISE21,000——
May 20, 2026Brown MelindaDirectorEXERCISE21,000——
May 20, 2026Frankel StanleyDirectorEXERCISE21,000——
May 20, 2026Buehler KevinDirectorEXERCISE21,000——
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 4.4/10.
BULLISH 8-K 7/10
Precision BioSciences announced new and late-breaking clinical data from the Phase 1 ELIMINATE-B tri
May 27, 2026
NEUTRAL 8-K 4/10
Precision BioSciences held its 2026 annual meeting on May 21, 2026, with roughly 86% of shares repre
May 26, 2026
NEUTRAL 8-K 4/10
Precision BioSciences reported Q1 2026 revenue of $10.8M (up from ~$0.1M YoY) and a net loss of $(0.
May 5, 2026
NEUTRAL DEFA14A 3/10
Precision BioSciences is filing a definitive proxy statement for its annual shareholder meeting, whi
Apr 8, 2026
NEUTRAL 8-K 4/10
Analysis based on filing metadata only — document content was unavailable. The filing is an 8-K with
Mar 12, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 4 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$29.60 mean target +385.2% upside Strong Buy (1.00)
$19.00 Low $60.00 High
MetricValue
Current Price$6.10
Target Low$19.00
Target Mean$29.60
Target Median$20.00
Target High$60.00
# Analysts5
RecommendationStrong Buy (1.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.67 $-0.81 $-0.50 68.5% -11.7% 0↑ 1↓ $0.0B 7677.8% 3
Next Q
2026-09-30
 $-0.65 $-0.72 $-0.51 64.8% -6.0% 1↑ 0↓ $0.0B 13438.5% 3
Current FY
2026-12-31
 $-2.49 $-3.12 $-1.70 31.5% -14.6% 1↑ 0↓ $0.0B -45.1% 3
Next FY
2027-12-31
 $-1.89 $-2.38 $-1.45 23.9% +1.1% 0↑ 1↓ $0.0B -33.4% 3

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.670
7d ago$-0.600-0.070
30d ago$-0.600-0.070
60d ago$-0.920+0.250
90d ago$-0.820+0.150
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 9, 2026 Oppenheimer INITIATE — Outperform
May 27, 2026 HC Wainwright & Co. REITERATE Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20264510090%
May 1, 20264510090%
Apr 1, 20264510090%
Mar 1, 20264510090%
Feb 1, 20264510090%
Jan 1, 20264510090%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 13, 2026
earnings_calendar
DTIL Q1 2026 Earnings Scheduled — 2026-05-13